An interventional study of Real-time fMRI Neurofeedback and Sham Real-time fMRI Neurofeedback in Opioid Use Disorder, Substance Use Disorder and Heroin Use Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 723rd largest by enrollment of the 1,098 interventional ones that give a count, is one of 89 that started in 2025, is one of 571 with no phase, and was the 1,163rd registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
University of Kentucky · Sites in United States
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 18–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 245 · Phase 3 99 · Phase 4 79
First in 1988; this study’s year is marked. 89 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 56 across the 1,098 interventional studies, 85 across the 122 observational. Of the 834 that completed or were terminated, 332 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 1,223 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
129 of the studies in Opioid-Related Disorders with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT05834478Phase 3Emory UniversityNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | 2027-02 |
| NCT05033028Phase 3NYU Langone HealthSmartphones for Opiate Addiction Recovery | 2027-06-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
Add all 129 to your calendar (.ics) → With an account.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Support groups are an important component of addiction treatment, where individuals at more stable stages of their recovery help others by sharing personal experiences. This phenomenon suggests that the brain states of individuals further along in their recovery process may be useful in guiding those who are at an earlier stage. In this project, the researchers will test this idea and develop a personalized therapeutic tool based on real-time fMRI neurofeedback, whereby individuals with heroin use disorder (iHUD) early in treatment will learn to modulate their own brain state to more closely align with iHUD who are at later stages of treatment. Specifically, iHUD exhibit heightened reactivity to naturalistic drug cues in brain networks underlying salience attribution, reward processing, executive function and others. This fMRI brain hyperactivity pattern is reduced, concomitant with craving reductions, with about 3 months of inpatient treatment. In this neurofeedback project, iHUD who are beginning treatment will view naturalistic drug cues and receive feedback about how similar their brain activity is to the target recovery pattern, learning to modulate their own brain activity to reduce drug cue reactivity and craving. This study will offer insights into the mechanisms of recovery in addiction, particularly as coordinated across individuals with shared experience and goals. If successful, the neurofeedback-based training may lead to new brain-based and personalized tools for recovery in this devastating disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive real-time fMRI neurofeedback reflecting their own brain activity during a drug-related movie.
Behavioral: Real-time fMRI Neurofeedback
Participants receive sham real-time fMRI neurofeedback yoked to a matched participant and unrelated to their own brain activity.
Behavioral: Sham Real-time fMRI Neurofeedback
Real-time feedback reflecting the similarity between participant's brain activity patterns and a predefined target while viewing a drug-related movie.
Real-time feedback yoked to another participant and not reflective of the participant's own brain activity.
Cue/Movie-induced Craving Score
Self-reported ratings of heroin craving on a 0-9 point scale, with higher scores indicating higher craving.
Time frame: Immediately before and immediately after neurofeedback procedure (average 17 min MRI scan)
Neurofeedback Score Change
Change in neurofeedback performance, reflecting participants' ability to modulate brain activity toward the predefined target pattern. Neurofeedback scores range 0-100, with higher scores indicating more similar brain activity to the target pattern.
Time frame: During each 20 minute neurofeedback training session. Participants complete 8 neurofeedback sessions over the course of 4 consecutive days.
| Milestone | Real Neurofeedback | Sham (Yolked) Neurofeedback |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Self-reported ratings of heroin craving on a 0-9 point scale, with higher scores indicating higher craving.
| score on a scale | Real Neurofeedback | Sham (Yolked) Neurofeedback |
|---|---|---|
| Day 1, immediately pre neurofeedback treatment, run 1 | 3.0 ± 2.75 | 4.60 ± 2.59 |
| Day 1, immediately post neurofeedback treatment, run 1 | 1.60 ± 2.46 | 4.60 ± 3.03 |
| Day 1, immediately pre neurofeedback treatment, run 2 | 1.78 ± 2.54 | 4.70 ± 3.53 |
| Day 1, immediately post neurofeedback treatment, run 2 | 1.11 ± 1.97 | 3.80 ± 3.52 |
| Day 2, immediately pre neurofeedback treatment, run 1 | 1.22 ± 2.17 | 3.50 ± 3.31 |
| Day 2, immediately post neurofeedback treatment, run 1 | 1.00 ± 2.29 | 4.00 ± 3.20 |
| Day 2, immediately pre neurofeedback treatment, run 2 | 1.33 ± 2.24 | 2.80 ± 3.36 |
| Day 2, immediately post neurofeedback treatment, run 2 | 1.11 ± 1.97 | 3.60 ± 3.34 |
| Day 3, immediately pre neurofeedback treatment, run 1 | 1.80 ± 2.10 | 4.30 ± 3.30 |
| Day 3, immediately post neurofeedback treatment, run 1 | 0.70 ± 1.34 | 4.00 ± 3.30 |
| Day 3, immediately pre neurofeedback treatment, run 2 | 0.80 ± 1.32 | 3.80 ± 3.19 |
| Day 3, immediately post neurofeedback treatment, run 2 | 0.50 ± 0.97 | 3.70 ± 3.50 |
| Day 4, immediately pre neurofeedback treatment, run 1 | 1.30 ± 1.83 | 3.70 ± 3.20 |
| Day 4, immediately post neurofeedback treatment, run 1 | 0.50 ± 1.08 | 3.00 ± 3.59 |
| Day 4, immediately pre neurofeedback treatment, run 2 | 1.30 ± 1.70 | 3.00 ± 3.39 |
| Day 4, immediately post neurofeedback treatment, run 2 | 0.90 ± 1.73 | 2.78 ± 3.49 |
Change in neurofeedback performance, reflecting participants' ability to modulate brain activity toward the predefined target pattern. Neurofeedback scores range 0-100, with higher scores indicating more similar brain activity to the target pattern.
Results for this outcome have not been posted.
Collected over From enrollment until end of last study visit, up to 10 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Real Neurofeedback | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Sham (Yolked) Neurofeedback | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(Years) | Real Neurofeedback | Sham (Yolked) Neurofeedback | Total |
|---|---|---|---|
| Mean | 44 ± 11 | 41 ± 7 | 43 ± 9 |
| Sex: Female, Male(Participants) | Real Neurofeedback | Sham (Yolked) Neurofeedback | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 9 | 10 | 19 |
| Race (NIH/OMB)(Participants) | Real Neurofeedback | Sham (Yolked) Neurofeedback | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 6 | 5 | 11 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Education(Years) | Real Neurofeedback | Sham (Yolked) Neurofeedback | Total |
|---|---|---|---|
| Mean | 12.80 ± 1.93 | 10.90 ± 2.18 | 11.80 ± 2.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Immediately following publication. No end date.
Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Specify Other Mechanism Researchers who provide a methodologically sound proposal. Any purpose. Proposals should be directed to NARC@mssm.edu. To gain access, data requestors will need to sign a data access agreement.
Ran from May 2025 to primary completion in Aug 2025, 3 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 3 months is below that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →